Rebastinib Tosylate

N/A

Report date: 2024/12/28 20:00:07
NME

Base Information

Drug NameRebastinib Tosylate
Drug Alias NameRebastinib瑞巴替尼RebastinibumDP-1919DCC-2036 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTEK receptor tyrosine kinase antagonistsVascular endothelial growth factor receptor antagonistsBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinaseVascular endothelial growth factor receptorTEK receptor tyrosine kinase
Therapy Area/IndicationsSolid tumoursLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDeciphera
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDeciphera Pharmaceuticals Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG